# Merck Group account plan

> Merck KGaA is a family-controlled German science and technology group in Life Science, Healthcare and Electronics, with €21,102 million of 2025 sales.

## At a glance

Merck KGaA, Darmstadt, Germany, is a science and technology company founded in 1668 that works in three sectors: Life Science, Healthcare and Electronics. In the US and Canada it operates as MilliporeSigma, EMD Serono and EMD Electronics. In FY2025 it reported net sales of €21,102 million (organic +3.1%), EBITDA pre of €6,109 million (28.9% margin) and profit after tax of €2,615 million; Asia-Pacific (€6,936 million) and Europe (€6,417 million) were its largest regions. It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026. The founding family holds 70.274% via E. Merck KG, and 29.726% of the share capital is listed in Frankfurt; Kai Beckmann has been Group CEO since 1 May 2026.

## Business units

- **Life Science** (€8,980 million FY2025 sales, 42% of group sales, 40% of EBITDA pre): Reagents, consumables, instruments, filtration, chromatography and single-use systems, and contract testing and manufacturing for labs, biotech and pharma (MilliporeSigma in North America). Since 1 January 2026 it reports as Process Solutions, Discovery Solutions and Advanced Solutions; H1 2026 sales were €4,677 million (organic +8.1%), with Process Solutions up 15.5% organically. Led by Jean-Charles Wirth.
- **Healthcare** (€8,607 million FY2025 sales, 41% of group sales, 47% of EBITDA pre): Specialty medicines (EMD Serono in the US and Canada) now organised in four franchises: Rare Diseases, Cardiometabolic, Fertility & Endocrinology and Specialty Care. H1 2026 sales were €4,203 million (organic -3.4%) as US generics hit Mavenclad, offset by the SpringWorks rare-disease portfolio. Led by Dan Pinhas Bar Zohar.
- **Electronics** (€3,515 million FY2025 sales, 17% of group sales, 13% of EBITDA pre): Materials, delivery systems and metrology and inspection for semiconductor and display makers, a pure-play business since Surface Solutions was sold in July 2025; Asia-Pacific generated 72% of sector sales. Semiconductor Solutions grew 12.2% organically in H1 2026 on AI-driven advanced nodes. Benjamin Hein succeeded Kai Beckmann as CEO Electronics.

## Strategic priorities

- **Three growth drivers**: Process Solutions, Rare Diseases and Semiconductor Solutions are positioned to generate up to 80% of growth in the medium term, with mid-single-digit organic sales growth targeted.
- **New strategic direction (May 2026)**: Four streams: focus on high-growth value drivers, shift selected portfolios to integrated workflow solutions, platform capabilities across businesses such as AI deployment, and sourcing innovation through M&A and in-licensing.
- **Integrated workflow solutions**: Merck is moving selected portfolios from standalone products to end-to-end offerings, as in bioprocessing (consumables, bioreactors, process analytics software) and in materials plus metrology for advanced chips.
- **Healthcare pipeline and margin**: Healthcare stays above a 30% EBITDA pre margin while R&D moves towards 25% of sales, with pipeline building focused on early and mid-stage external innovation.
- **Sustainability**: Climate neutrality by 2040; Scope 1 and 2 emissions are down 60% versus 2020, with renewable purchased electricity at 64% toward 80% by 2030.

## Latest results

In H1 2026 net sales were €10,568 million (+0.3%; organic +3.5%) and EBITDA pre €3,129 million (+4.4%; organic +7.2%), a 29.6% margin; free cash flow rose to €565 million from €194 million. Q2 2026 sales grew 4.1% organically to €5,434 million, while EBIT fell 15.5% to €753 million on €189 million of restructuring expenses. Life Science and Electronics grew organically while Healthcare declined on US Mavenclad generics. Guidance was raised for the second time to net sales of €21.0-21.8 billion, EBITDA pre of €5.9-6.3 billion and EPS pre of €7.90-8.60. Net financial debt was €9,207 million at 30 June 2026.

## Investments and deals

- **Bio-Techne acquisition**: Agreed on 25 June 2026 at US$73 per share, a company value of around US$11.3 billion (€9.9 billion); close expected end-2026/early 2027, with run-rate cost synergies of approximately €140 million by year three.
- **SpringWorks Therapeutics**: Acquired on 1 July 2025 for an enterprise value of approximately €3 billion, creating the Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly).
- **JSR chromatography business**: Acquisition of JSR Corporation's chromatography business (Amsphere Protein A resins) completed in March 2026.
- **Manufacturing sites**: Over €7 billion invested in over 30 new or expanded sites since 2021, including the €500 million Kaohsiung megasite in Taiwan and a €150 million filter plant at Blarney, Cork.
- **Surface Solutions divestment**: Pigments business sold to Global New Material International Holdings for €669 million, closed 31 July 2025.

## Challenges and risks

- **Mavenclad generics in the US**: Two US dosing-regimen patents were held invalid, opening the market to generics; 2026 guidance assumes no US Mavenclad sales from August 2026.
- **Currency headwinds**: Currency effects cut FY2025 sales by 3.7%, pushing sales below the original guidance.
- **Geopolitics and supply chain**: Risks include Russia-Ukraine, the Taiwan Strait, US-China export controls, and the Gulf conflict and Strait of Hormuz for supply chains and raw materials.
- **Pricing and competition**: Drug pricing pressure, overcapacity and price pressure in bioprocessing, semiconductor cyclicality and Chinese competition are listed among the most significant risks.
- **Weak lab and consumer electronics demand**: US policy changes affecting academic and government labs and a weak China held Science & Lab Solutions flat, and weak consumer electronics hit Optronics.

## What leadership says

> "only a clear plan and disciplined execution will move us closer to the sustainable, profitable growth we are building for our company." — Kai Beckmann, Chairman of the Executive Board and Group CEO, Q2 2026 investor and analyst call, 6 August 2026

> "In short, we will optimize for speed and scalability where it matters." — Kai Beckmann, Chairman of the Executive Board and Group CEO, Q1 2026 call with strategic direction update, 13 May 2026

> "Most importantly, we transform in times of growth." — Belén Garijo, Chair of the Executive Board and CEO, Semafor Signal Interview, 14 November 2025


## Where a supplier can help

- **Bio-Techne integration**: Integration is the stated priority after the Bio-Techne deal, with about €140 million of cost synergies targeted, a fit for integration, systems and process consultancies.
- **AI platform capabilities**: AI deployment is one of the shared platform capabilities in the new strategic direction, opening doors for data, AI and digital workflow suppliers.
- **Integrated workflow offerings**: The shift from standalone products to end-to-end offerings in bioprocessing and chip materials creates room for software, analytics and equipment partners.
- **New plant start-ups**: Startup of new sites such as Blarney in Ireland and Kaohsiung in Taiwan, and the move from building to loading capacity, needs automation, maintenance and operations support.
- **Supply-chain resilience**: Geopolitical and Strait of Hormuz supply-chain risks point to demand for sourcing, logistics and raw-material risk services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Merck Annual Report 2025](https://reports.merckgroup.com/en/annualreport/2025/_assets/downloads/entire-merck-ar25.pdf)

Annual report · 2026-03-05

- Merck KGaA (Darmstadt) is a science and technology group with three business sectors, Life Science, Healthcare and Electronics; the founding family, in its 13th generation, holds 70.274% via E. Merck KG, and 29.726% of the share capital trades on the Frankfurt Stock Exchange. In the US and Canada it operates as MilliporeSigma, EMD Serono and EMD Electronics. 62,461 employees at 31 December 2025.
- FY2025: net sales €21,102 million (-0.3%; organic +3.1%, currency -3.7%, portfolio +0.4%), EBITDA pre €6,109 million (+0.6%; organic +5.6%) at a 28.9% margin, profit after tax €2,615 million, EPS pre €8.34, operating cash flow €3,932 million (-14.3%). Dividend proposed unchanged at €2.20.
- Sector mix: Life Science 42% of sales / 40% of EBITDA pre, Healthcare 41% / 47%, Electronics 17% / 13%. By region: Asia-Pacific €6,936 million, Europe €6,417 million, North America €5,517 million, Latin America €1,447 million, Middle East and Africa €785 million.
- Life Science (€8,980 million) returned to growth: Process Solutions grew 10.7% organically on new customer projects and a normalizing market; a customer-centric structure (Process Solutions, Discovery Solutions, Advanced Solutions) took effect on 1 January 2026. Acquisition of JSR Corporation's chromatography business signed.
- Healthcare (€8,607 million, EBITDA pre margin 35.8%): SpringWorks Therapeutics acquired on 1 July 2025 (enterprise value of approximately €3 billion), creating a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly); Mavenclad reached €1,194 million but two US dosing-regimen patents were held invalid, opening the US to generics.
- Electronics (€3,515 million) is now a pure-play semiconductor and optronics business after selling Surface Solutions (closed 31 July 2025, €669 million); Semiconductor Materials grew 8.2% organically on AI demand, while Delivery Systems & Services fell on delayed customer projects; €500 million Kaohsiung (Taiwan) megasite inaugurated.
- Strategy: three growth drivers (Process Solutions, Rare Diseases, Semiconductor Solutions) expected to generate up to 80% of medium-term growth; mid-single-digit organic sales growth targeted over the medium term; capex-to-sales to normalize after €7 billion invested in over 30 sites since 2021.
- Net financial debt rose to €8,619 million (SpringWorks; US$4 billion bond in August 2025); ratings A (S&P) and A3 (Moody's). Dividend policy: 20% to 25% of EPS pre.
- 2026 outlook (March): net sales €20.0-21.1 billion (organic -1% to +2%), EBITDA pre €5.5-6.0 billion, free cash flow €1.5-2.0 billion (new KPI); Healthcare to decline organically on US Mavenclad generics. Kai Beckmann succeeds Belén Garijo as CEO on 1 May 2026.

### [Half-Yearly Financial Report 2026 (Q2 2026)](https://www.merckgroup.com/content/dam/web/corporate/non-images/press-kits/q2-2026/en/2026-Q2-Report-EN.pdf)

Interim report · 2026-08-06

- H1 2026: net sales €10,568 million (+0.3%; organic +3.5%, currency -3.3%), EBITDA pre €3,129 million (+4.4%; organic +7.2%), margin 29.6%; EPS pre €4.27; free cash flow €565 million (H1 2025: €194 million).
- Q2 2026: sales €5,434 million (+3.4%, organic +4.1%), EBITDA pre €1,599 million (+9.4%, organic +9.3%), margin 29.4%; EBIT fell 15.5% to €753 million on €189 million of restructuring expenses.
- Life Science H1 sales €4,677 million (organic +8.1%): Process Solutions +15.5% organic (€2,082 million) on downstream and single-use demand, Discovery Solutions +1.8%, Advanced Solutions +4.2%; EBITDA pre margin 28.8%.
- Healthcare H1 sales €4,203 million (organic -3.4%, SpringWorks portfolio effect +4.9%): Specialty Care -6.3% (Mavenclad generics in the US, Bavencio), Rare Diseases €209 million; EBITDA pre down 7.2% to €1,465 million (margin 34.9%) with R&D up 23.1%.
- Electronics H1 sales €1,688 million (organic +7.9%): Semiconductor Solutions +12.2% organic on AI-driven advanced nodes, Optronics -2.3%; EBITDA pre €526 million (+39.2%), margin 31.2%, helped by €43 million from selling OLED patents.
- Bio-Techne: agreement (25 June 2026) to buy Bio-Techne for US$73 per share, a company value of around US$11.3 billion (€9.9 billion); close expected end-2026/early 2027. JSR chromatography acquisition closed; Saturnus Bio controlled from June 2026.
- Guidance raised: net sales €21.0-21.8 billion (organic +1% to +3%), EBITDA pre €5.9-6.3 billion, free cash flow €1.8-2.3 billion, EPS pre €7.90-8.60.
- Kai Beckmann became Chairman of the Executive Board and Group CEO on 1 May 2026; Benjamin Hein succeeded him as CEO Electronics. Net financial debt €9,207 million; 62,136 employees.

### [Q2 2026 investor and analyst conference call (transcript)](https://financialfilings.com/filings/merck-kgaa/call-meeting-transcript/2026/57622348/)

Executive talk · Kai Beckmann, Chairman of the Executive Board and Group CEO · 2026-08-06

- Kai Beckmann, Group CEO since May 2026, called Q2 "a pretty robust quarter": organic sales +4.1%, organic EBITDA pre +9.3%, margin up 1.6 points to 29.4%; full-year guidance raised for the second time.
- Bio-Techne (signed 25 June) is his first big proof point: expected to add close to 5% to group sales growth and about 10% to Life Science, immediately accretive to the EBITDA pre margin, EPS pre accretive in year three, run-rate cost synergies of about €140 million.
- Process Solutions grew 15% organically, helped by temporary Asian buying, exceptional China equipment orders and one-off integrated-workflow orders; full year expected at the upper end of the 8% to 12% range, with any destocking more likely in 2027.
- Electronics: Semiconductor Solutions +17% organic on AI-driven advanced logic and memory; leading-edge customers capacity-constrained into 2027; memory shortage seen lasting at least to H2 2027; Optronics hit by weak consumer electronics.
- Healthcare: Mavenclad US eroding more slowly than analogs, Europe up 32% in Q2; Pergoveris US filing accepted but approval uncertain; the anti-CEACAM5 ADC will be developed alone rather than partnered.
- 2027: Beckmann says organic growth should be in line with the 2025 Capital Markets Day projections, despite tough Mavenclad and Process Solutions comparisons.
- Priorities after Bio-Techne: integration, replenishing the early-stage healthcare pipeline, strengthening Life Science and Electronics; CFO flags fast deleveraging after closing.

### [Q1 2026 investor and analyst conference call, with strategic direction update (transcript)](https://financialfilings.com/filings/merck-kgaa/call-meeting-transcript/2026/48443154/)

Executive talk · Kai Beckmann, Chairman of the Executive Board and Group CEO · 2026-05-13

- First call as Group CEO (13 May 2026): Kai Beckmann called Q1 "a solid start to 2026 despite global challenges" (organic sales +2.9%, organic EBITDA pre +5.3%) and raised 2026 guidance to €20.4-21.4 billion sales and €5.7-6.1 billion EBITDA pre.
- Unveiled a new strategic direction built on four streams: focus on high-growth value drivers, shift selected portfolios to integrated workflow solutions, platform capabilities across businesses, and sourcing innovation through M&A and in-licensing.
- Framing: AI compresses discovery, so advantage shifts to companies that can "rapidly validate, manufacture, scale, and commercialize innovations"; Merck positions itself as both an enabler and a user of AI.
- Mid-term guidance from the 2025 Capital Markets Day confirmed; strategy impact expected progressively, with a standalone investor event planned for next year.
- M&A scope broadened but disciplined: IRR above WACC, EPS pre accretion after synergies, strong investment-grade rating; expansion into equipment and tools only where it drives materials and consumables.
- Healthcare: kept above 30% EBITDA pre margin while R&D moves toward 25% of sales; pipeline building focused on early and mid-stage; four new franchises (Rare Diseases, Cardiometabolic, Fertility & Endocrinology, Specialty Care).
- Process Solutions +16% in Q1 (above €1 billion of quarterly sales for the first time since Q1 2023); semiconductor materials grew double digit; Middle East and Africa only 3% of group sales.

### [Q4 and full-year 2025 investor and analyst conference call (transcript)](https://financialfilings.com/filings/merck-kgaa/call-meeting-transcript/2026/48442329/)

Executive talk · Belén Garijo, Chair of the Executive Board and CEO · 2026-03-05

- Full-year 2025 call (5 March 2026), Belén Garijo's last as CEO: 2025 delivered solid organic sales and EBITDA pre growth in a challenging macro and geopolitical environment, meeting the latest guidance for the group and all sectors.
- Q4 2025: organic sales +2.6%, organic EBITDA pre +3.1%; leverage improved to 1.4 times net debt to EBITDA pre; stable €2.20 dividend proposed, a 15th year of stable or rising dividends.
- Garijo: Life Science back to growth (Process Solutions around 10% organic in 2025); Rare Diseases a new Healthcare pillar; Electronics now a pure-play business "right at the center of the rise in artificial intelligence".
- Healthcare committed to EBITDA pre margins north of 30% and R&D around 20% of sales; three growth engines: Rare Diseases, CM&E and Fertility.
- Kai Beckmann (incoming CEO) gave 2026 guidance: sales €20-21.1 billion, EBITDA pre €5.5-6 billion, EPS pre €7.10-8, assuming no US Mavenclad sales from March and excluding a US Pergoveris launch.
- Sustainability: Scope 1 and 2 emissions down 60% versus 2020; more than 5,000 greener Life Science products with over €300 million of sales.
- Garijo's legacy claim: sales up 20% since 2020, earnings faster and net debt down 20%, via a "string of pearls" M&A approach (Mirus Bio, Unity-SC, SpringWorks).

### [Belén Garijo's prescription for Germany's Merck (Semafor, The Signal Interview)](https://www.semafor.com/article/11/14/2025/beln-garijos-prescription-for-germanys-merck)

Executive talk · Belén Garijo, Chair of the Executive Board and CEO · 2025-11-14

- Semafor's "Signal Interview" (14 November 2025) with Belén Garijo, then CEO, as she prepared to hand over to Kai Beckmann in May 2026.
- Her diagnosis approach comes from medicine: "I act on the root cause rather than on the symptoms."
- Family ownership (13th generation, board of partners approving large capital allocation) supports long-term decisions and a shift from scale acquisitions to a "string of pearls" approach; it let her resist pressure to do more life science deals a few years ago.
- "Most importantly, we transform in times of growth": cost and efficiency work started during the pandemic boom.
- Defends the three-sector model as "a risk-reward model that fits… family ownership"; acknowledges a "conglomerate discount" and answers it with synergies in manufacturing, innovation and AI ("bioconvergence").
- Built a "One Merck" culture: cross-sector talent moves, group-wide incentive scorecard, joint work among the three R&D heads; almost 40% of senior leaders are women.
- Will not rename the company: "we are Merck. The real Merck." Merck's US arm agreed with the White House to cut prices of some IVF drugs.

## Questions about Merck Group

### What does Merck KGaA do?

Merck KGaA, Darmstadt, Germany, is a science and technology company in Life Science, Healthcare and Electronics, operating in the US and Canada as MilliporeSigma, EMD Serono and EMD Electronics.

### What was Merck KGaA's revenue in 2025?

Net sales were €21,102 million in FY2025, with EBITDA pre of €6,109 million and profit after tax of €2,615 million.

### How many employees does Merck KGaA have?

It had 62,461 employees at 31 December 2025 and 62,136 at 30 June 2026.

### Who leads Merck KGaA?

Kai Beckmann became Chairman of the Executive Board and Group CEO on 1 May 2026, succeeding Belén Garijo; Helene von Roeder is CFO.

### What is Merck KGaA's strategy?

It focuses on three growth drivers (Process Solutions, Rare Diseases, Semiconductor Solutions), integrated workflow solutions and M&A such as the Bio-Techne deal, targeting mid-single-digit organic growth.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
